Capital BlueCross surgical sleep apnea Coverage Update

Coverage Criteria and Medical Necessity

Palatopharyngoplasty (Adults)

Covered when ALL of the following are met:

Adult palatopharyngoplasty criteria: 1) Clinically significant OSA defined by AHI or RDI ≥15, OR AHI or RDI ≥5 with ≥1 OSA-related sign/symptom (e.g., excessive daytime sleepiness, hypertension, cardiovascular disease, or stroke); 2) Failure of an adequate trial of CPAP or an adequate trial of an oral appliance; 3) Patient is an appropriately selected adult.see node text

Procedures listed: uvulopalatopharyngoplasty, uvulopharyngoplasty, uvulopalatal flap, expansion sphincter pharyngoplasty, lateral pharyngoplasty, palatal advancement pharyngoplasty, relocation pharyngoplasty.

Hypopharyngeal-targeted surgeries (Adults)

Covered when ALL of the following are met:

Hypopharyngeal obstruction surgical criteria: 1) Clinically significant OSA (AHI or RDI ≥15, OR AHI or RDI ≥5 with ≥1 OSA-related sign/symptom); 2) Objective documentation of hypopharyngeal obstruction; 3) Failure of an adequate trial of CPAP or an adequate trial of an oral appliance; 4) Appropriately selected adult candidate.see node text

Includes mandibular-maxillary advancement (MMA), hyoid suspension, surgical modification of the tongue.

Adenotonsillectomy (Pediatrics)

Covered when ALL of the following are met:

Pediatric adenotonsillectomy criteria: 1) Clinically significant OSA with hypertrophic tonsils and either: AHI or RDI ≥5 per hour; OR AHI or RDI ≥1.5 per hour in a child with excessive daytime sleepiness, behavioral problems, or hyperactivity.see node text

Pediatric population specified.

Hypoglossal nerve stimulation (Adults)

Covered when ALL of the following are met for adults:

Adult hypoglossal nerve stimulation criteria: 1) Age ≥18 years; 2) AHI ≥15 and ≤100 with ≤25% central apneas; 3) CPAP failure (residual AHI ≥15 despite CPAP use) or inability to tolerate CPAP (use <4 hr/night on ≥5 nights/week) or inability to use CPAP; 4) BMI ≤35 kg/m2; 5) Absence of complete concentric collapse at the soft palate level (assessed e.g., by DISE).see node text

Device-specific indications (Inspire) referenced.

Hypoglossal nerve stimulation (Adolescents with Down syndrome)

Covered when ALL of the following are met:

Adolescent Down syndrome UAS criteria: 1) Age 13 to 18 years; 2) AHI >10 and <50 with ≤25% central apneas after prior adenotonsillectomy; 3) Have either tracheotomy or be ineffectively treated with CPAP due to noncompliance, intolerance, persistent symptoms despite compliance, or refusal; 4) BMI ≤95th percentile for age; 5) Absence of complete concentric collapse at the soft palate level.see node text

Specific to Down syndrome adolescents/young adults.

Investigational / Not Medically Necessary Procedures

Procedures considered investigational (Not covered):

Investigational procedures: Laser-assisted palatoplasty/LAUP; radiofrequency volumetric tissue reduction of the palatal tissues; radiofrequency volumetric tissue reduction of the tongue (with or without palatal RF); palatal stiffening procedures (e.g., cautery-assisted palatal stiffening, sclerosing agent injection, palatal implants); tongue base suspension; all other minimally invasive surgical procedures not described as medically necessary; implantable hypoglossal nerve stimulators for indications other than those listed; phrenic nerve stimulation for central sleep apnea.N/A

These procedures are investigational due to insufficient evidence.

Coverage by intervention

Coverage stance is split by intervention and indication:

Phrenic nerve stimulation for CSA: Investigational; therefore, not covered for central sleep apnea per coding list and policy statement.

Although clinical trials exist, policy lists phrenic nerve stimulation as investigational.

Surgical treatments for OSA: Some surgical procedures are covered when medically necessary (specific procedure codes listed) while other surgical treatments are considered investigational and not covered (specific codes listed).

Coverage depends on the specific procedure code as listed in policy.

Noninvasive therapies prior to invasive procedures: Treatment of reversible underlying causes and trials of CPAP, supplemental oxygen, bilevel PAP, or respiratory stimulants are first-line; invasive therapies typically considered after noninvasive therapy failure.

Supports step therapy prior to implantation.

Hypoglossal nerve stimulation — selection guidance

HNS may be appropriate in select patients who meet study-based selection criteria:

HNS selection: Age and anatomy considerations: adult selection commonly from study populations (age thresholds varied by studies); moderate-to-severe OSA with <25% central apneas; prior CPAP failure or intolerance; lower BMI thresholds used in trials (examples: BMI ≤32 kg/m2 or BMI ≤35 kg/m2); favorable pattern of palatal collapse and absence of complete concentric collapse.

Derived from clinical trial selection criteria and clinical input; policy notes variability in study cutoffs.

Policy-level coverage statements and historical modifications

Investigational - Phrenic Nerve Stimulation for CSA: Phrenic nerve stimulation for central sleep apnea has been added as investigational.

Added with associated coding per 01/22/2025 update.

Hypoglossal Nerve Stimulation (HNS) criteria changes: Adult HNS criteria were updated to allow AHI ≤100; pediatric age and BMI language adjusted (example: pediatric lower age modified to 13).AHI ≤100 for adults; pediatric age ≥13 in later update

Multiple policy history entries document these changes.

The policy lists a group of minimally invasive palatal and tongue procedures that are regarded as investigational because current evidence does not demonstrate a clear net health benefit. Examples include laser-assisted palatoplasty, radiofrequency volumetric tissue reduction of the palate, radiofrequency volumetric reduction of the tongue (with or without palatal RF), palatal stiffening procedures (for example, cautery-assisted palatal stiffening, injection of sclerosing agents, and palatal implants), tongue base suspension, and other similar minimally invasive techniques. These interventions are also considered investigational when used to treat isolated snoring in the absence of documented obstructive sleep apnea.

Phrenic nerve stimulation for the treatment of central sleep apnea (CSA) is designated investigational in all situations by this policy. Although clinical trials and observational studies are described in the evidence base, the policy was updated to add an investigational statement and associated coding for phrenic nerve stimulation (see policy history entries).

The policy explicitly lists procedure and device codes that are categorized as Investigational; therefore, not covered. Examples provided in the policy coding tables include codes associated with investigational surgical treatments for OSA such as 41512, 41530, 42299, C9727, S2080, and codes associated with investigational phrenic nerve stimulation for CSA such as 93150, 33277–33281, 33287–33288 and related HCPCS entries. Providers should refer to the coding tables in the policy when determining coverage vs investigational status for a specific billed code.

Per the policy history, procedure code 41512 has been moved to the noncovered coding table (not medically necessary / noncovered). This coding relocation is documented in the 01/22/2025 update and reflected in the policy coding tables.

Minimally invasive palatal and tongue procedures — including laser-assisted palatoplasty, radiofrequency volumetric tissue reduction of the palate or tongue, palatal stiffening procedures (cautery-assisted stiffening, sclerosing injections, palatal implants), and tongue base suspension — are considered investigational and therefore not medically necessary when criteria for medical necessity are not met. The policy notes insufficient evidence of clinically meaningful improvement in outcomes for these techniques.

The policy summarizes that evidence is insufficient for many minimally invasive procedures and some device-based therapies. For example, single RCTs and small trials of laser-assisted uvulopalatoplasty and various radiofrequency palatal procedures have shown limited or inconsistent effects on AHI and symptoms. Palatal stiffening trials yielded mixed results across RCTs, and tongue base suspension is supported only by small feasibility trials. Overall, the body of evidence is judged inadequate to establish improvement in net health outcomes for these listed procedures.

The policy history documents that on 01/22/2025 phrenic nerve stimulation for central sleep apnea was added to the policy as investigational with associated coding changes. This administrative update explicitly classifies phrenic nerve stimulation for CSA as investigational (not covered).

Coding and Identifiers

Regulatory device identifiers referencedmixed

K982717	Radiofrequency ablation 510(k) number (Somnoplasty)
K040417	Palatal Implant 510(k) number (Pillar Palatal Implant)
K122391	Tongue base suspension 510(k) number (AIRvance)
K111179	Tongue base suspension 510(k) number (Encore/PRELUDE III)
P130008	Inspire hypoglossal nerve stimulation PMA/IDE identifier

Investigational; therefore, not covered: Surgical Treatments for OSAmixedNot Covered

41512	Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA'
41530	Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA'
42299	Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA'
C9727	Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA'
S2080	Procedure code listed under 'Investigational; therefore, not covered: Surgical Treatments for OSA'

Investigational; therefore, not covered: Phrenic Nerve Stimulation for Central Sleep ApneamixedNot Covered

93150	Listed under 'Investigational; therefore, not covered: Phrenic Nerve Stimulation for Central Sleep Apnea'
33277	Procedure code variant listed under investigational phrenic nerve stimulation
33278	Procedure code variant listed under investigational phrenic nerve stimulation
33279	Procedure code variant listed under investigational phrenic nerve stimulation
33280	Procedure code variant listed under investigational phrenic nerve stimulation
33281	Procedure code variant listed under investigational phrenic nerve stimulation
33287	Procedure code variant listed under investigational phrenic nerve stimulation
33288	Procedure code variant listed under investigational phrenic nerve stimulation
C1823	HCPCS code listed in the phrenic nerve stimulation group

Covered when medically necessary: Surgical Treatments for OSAmixedCovered

42826	Procedure code listed under 'Covered when medically necessary: Surgical Treatments for OSA'
21685	Procedure code variant listed under covered surgical treatments
41120	Procedure code variant listed under covered surgical treatments
41130	Procedure code variant listed under covered surgical treatments
41599	Procedure code variant listed under covered surgical treatments
42145	Procedure code variant listed under covered surgical treatments
42820	Procedure code variant listed under covered surgical treatments
42821	Procedure code variant listed under covered surgical treatments
42825	Procedure code variant listed under covered surgical treatments
64568	Procedure code (asterisked) listed under covered surgical treatments

1–10 of 16

1/2

Policy identifiermixed

MP 1.128

Policy number referenced in coding history and updates

Coding changes and mentioned procedure codes (historical/current status referenced)mixed

41512	Procedure code mentioned as moved to noncovered and earlier MN
42975	Procedure code previously added then later removed from policy
64582-64584	Codes added in 12/01/2021 Administrative Update
0466T-0468T	Codes deleted in 12/01/2021 Administrative Update
21299	Procedure code added then later removed per 01/22/2025
31600	Procedure code added then later removed per 01/22/2025
31601	Procedure code added then later removed per 01/22/2025
41120	Procedure code added earlier per policy history
41130	Procedure code added earlier per policy history
42830-31	Procedure codes added earlier per policy history

1–10 of 14

1/2

inv-23: Apnea/Hypopnea Index (AHI) thresholds — key thresholds used for eligibility

Standard adult surgical thresholdClinically significant OSA: AHI or RDI ≥15 events/hour (or AHI/RDI ≥5 with ≥1 OSA-related sign or symptom)

Hypoglossal nerve stimulation (adult) baselineAHI ≥15 events/hour

Hypoglossal nerve stimulation (adult) upper limitAHI ≤100 events/hour (added 08/13/2024)

Adolescent (Down syndrome) rangeAHI >10 and <50 events/hour for ages 13–18 after prior adenotonsillectomy

inv-24: BMI threshold — BMI ≤35 kg/m2 for adult hypoglossal nerve stimulation.

Provider Responsibilities, Authorization, and Documentation

Prior Authorization

Prior Trial Requirement

Prior trial requirement: A prior trial and failure or intolerance of continuous positive airway pressure (CPAP) — or an adequate trial of an oral appliance where specified — is required before many surgical therapies for obstructive sleep apnea (OSA) will be considered medically necessary. Documentation should include objective sleep study results (AHI or RDI) and evidence that the member either failed CPAP (residual AHI ≥15 or inability/unwillingness to use CPAP ≥4 hours/night for ≥5 nights/week) or failed/intolerant of an oral appliance when applicable.

CPAP is preferred first-line therapy for most patients; oral appliances may be first-line for a smaller number of patients.
Prior CPAP failure may be defined as residual AHI ≥15 or insufficient use (≥4 hrs/night for ≥5 nights/week) or intolerance.

Step Therapy

First-line Therapy Precedence

First-line therapy precedence: Continuous positive airway pressure (CPAP) is the preferred first-line treatment for most patients with sleep-disordered breathing. Oral appliances are an alternative first-line option for a subset of patients; surgical or invasive interventions are generally considered only after adequate trials of noninvasive therapies have failed.

Background and Context

Obstructive sleep apnea (OSA) is characterized by repetitive upper airway collapse during sleep, leading to hypoxemia, fragmented sleep, and excessive daytime sleepiness. OSA is associated with cardiovascular and neurocognitive consequences, which motivates treatment when clinically significant (commonly defined by indices such as the Apnea–Hypopnea Index (AHI)). Surgical and device-based therapies aim to reduce airway collapse or stabilize respiratory drive; selection of invasive therapies is typically reserved for patients with documented OSA who have failed or are intolerant of first-line noninvasive therapies (for example, continuous positive airway pressure). The policy distinguishes OSA from central sleep apnea (CSA), the latter involving reduced ventilatory drive and for which different therapies, including phrenic nerve stimulation in trials, have been evaluated but are here classified investigational.

Definitions and Key Terms

inv-41: Apnea/Hypopnea Index (AHI) — definition of events per hour of recorded sleep.

AHI definition (general)AHI is the total number of apnea or hypopnea events per hour of recorded sleep

Alternate phrasingAHI is the average number of apneas or hypopneas per hour of sleep

Usage noteAHI used to define severity and eligibility for surgical interventions in policy

inv-42: Respiratory Disturbance Index (RDI) — definition.

RDI definitionRespiratory Disturbance Index (RDI) is the total number of apnea or hypopnea events per hour of recording time

Synonym noteRDI is often used synonymously with AHI in the policy

OpenPayer

Surgical Treatment of Sleep Apnea and Snoring

Coverage Criteria and Medical Necessity

Coding and Identifiers

Provider Responsibilities, Authorization, and Documentation

Background and Context

Definitions and Key Terms